RECENTLY ACTIVATED ALLIANCE TRIALS

Alliance A082402 - Involved-station, intensity-modulated post-operative radiation therapy (I²-PORT) for resected non-small cell lung cancer with residual mediastinal adenopathy after neoadjuvant therapy (ypN2)

Overview: This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to the standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have remaining lymph node cancer after surgery. Radiation therapy uses high-energy X-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Intensity-modulated radiation therapy is a type of three-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Adding I²-PORT radiation therapy to standard therapy may be more effective than standard therapy alone in reducing the risk of cancer returning in those who have undergone surgery for NSCLC.

Study Co-chair: David Kozono, MD, PhD | Harvard Medical School
Study Co-chair:Jeremy Brownstein, MD | The Ohio State University Comprehensive Cancer Center
Activated: 03/14/2026 | To learn more about the trial, visit ClinicalTrials.gov or read the news story.
ClinicalTrials.gov Identifier: NCT07293247.

Alliance A072301 - Phase III trial of radiotherapy followed by adjuvant temozolomide in combination with the IDH inhibitor vorasidenib vs. placebo in IDH-mutated newly-diagnosed grade 3 astrocytomas

Overview: This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Vorasidenib citrate blocks the proteins made by the mutated IDH1 and IDH2 genes, which may help keep tumor cells from growing. It is a type of enzyme inhibitor and a type of targeted therapy. Adding vorasidenib to the usual treatment, temozolomide, may be more effective than temozolomide alone in treating patients with newly diagnosed grade 3 astrocytoma after radiation therapy.

Study Chair: Ugonma Chukwueke, MD | Dana-Farber Cancer Institute 
Activated: 03/06/2026 | To learn more about the trial, visit ClinicalTrials.gov or read the news story.
ClinicalTrials.gov Identifier: NCT07215910.

Alliance A042302 - Phase III evaluation of fixed duration zanubrutinib plus sonrotoclax-based therapy compared to continuous zanubrutinib in previously untreated older patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Overview: This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Zanubrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Giving sonrotoclax and zanubrutinib may be more effective than zanubrutinib alone for the treatment of untreated CLL/SLL.

Study Chair: Jennifer Brown, MD, PhD | Dana-Farber Cancer Institute 
Activated: Activated 03/06/2026 | To learn more about the trial, visit ClinicalTrials.gov or read the news story.
ClinicalTrials.gov Identifier: NCT07321652.